Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Eli Lilly out-licenses migraine candidate to CoLucid Pharmaceuticals

Executive Summary

CoLucid Pharmaceuticals Inc., a start-up founded just a few months ago, in-licensed its first candidate from Eli Lilly & Co., the Phase I small-molecule 5HT1F agonist LY573144 for migraine and headache pain. CoLucid holds exclusive worldwide development and commercialization rights, along with the right to sublicense.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies